High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma
Status:
Terminated
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This study is being done to determine if an investigational cancer treatment called
vorinostat combined with fractionated stereotactic radiation therapy (FSRT) is effective in
treating recurrent high grade gliomas. The main goal of this research study is to determine
the highest dose of vorinostat that can be given to patients with recurrent tumors. The study
will also determine the potential side effects and safety of these treatment combinations.
Vorinostat is a small molecule inhibitor of histone deacetylase (HDAC). HDAC inhibitors help
unravel the deoxyribonucleic acid (DNA) of the cancer cells and make them more susceptible to
the treatment with radiation.